Results 31 to 40 of about 1,537,551 (243)

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

open access: yesJournal of Hematology & Oncology, 2016
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including ...
L. Sanchez   +3 more
semanticscholar   +1 more source

Targeting rapid TKI‐induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia

open access: yesMolecular Oncology, EarlyView.
Adaptive ERK reactivation hinders FLT3 tyrosine kinase inhibitor (TKI) treatment in FLT3/ITD acute myeloid leukemia. Here, we report that FLT3 TKI treatment rapidly induces AXL expression and upregulation that is temporally associated with the adaptive ERK reactivation.
Tessa S. Seale   +9 more
wiley   +1 more source

Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies [PDF]

open access: yesarXiv, 2023
Alzheimer's disease (AD) is a prevalent, progressive, and ultimately fatal neurodegenerative disorder that is defined pathologically by the accumulation of amyloid plaques and tau neurofibrillary tangles in the brain. There remains an unmet need for therapies that can halt or slow the course of AD. To address this need, the FDA has provided a mechanism,
arxiv  

Complete De Novo Assembly of Monoclonal Antibody Sequences

open access: yesScientific Reports, 2016
De novo protein sequencing is one of the key problems in mass spectrometry-based proteomics, especially for novel proteins such as monoclonal antibodies for which genome information is often limited or not available.
Ngoc Hieu Tran   +6 more
semanticscholar   +1 more source

Emerging new therapeutic antibody derivatives for cancer treatment

open access: yesSignal Transduction and Targeted Therapy, 2022
Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells.
Shijie Jin   +7 more
semanticscholar   +1 more source

The accumulation of myeloid‐derived suppressor cells participates in abdominal infection‐induced tumor progression through the PD‐L1/PD‐1 axis

open access: yesMolecular Oncology, EarlyView.
This study explores how sepsis affects GC progression by creating an immunosuppressive environment. Our findings reveal that sepsis promotes immune dysregulation, enhancing tumor growth and metastasis. Targeting the PD‐1/PD‐L1 pathway with monoclonal antibodies shows potential for restoring immune function and improving outcomes in cancer patients ...
Yiding Wang   +10 more
wiley   +1 more source

Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PD‐L1 immunotherapy in arm A of the NSGO‐OV‐UMB1/ENGOT‐OV30 trial

open access: yesMolecular Oncology, EarlyView.
Using mass cytometry, we analyzed serial blood samples from patients with relapsed epithelial ovarian cancer (EOC) treated with oleclumab–durvalumab combination immunotherapy in the NSGO‐OV‐UMB1/ENGOT‐OV30 trial. Our analysis identified potential predictive, monitoring, and response biomarkers detectable through liquid biopsy. These findings facilitate
Luka Tandaric   +11 more
wiley   +1 more source

Dynamic Optimization for Monoclonal Antibody Production [PDF]

open access: yesarXiv, 2023
This paper presents a dynamic optimization numerical case study for Monoclonal Antibody (mAb) production. The fermentation is conducted in a continuous perfusion reactor. We represent the existing model in terms of a general modeling methodology well-suited for simulation and optimization. The model consists of six ordinary differential equations (ODEs)
arxiv  

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

open access: yesBlood, 1994
Murine monoclonal antibody 2B8 specifically recognizes the CD20 phosphoprotein expressed on the surface of normal B lymphocytes and B-cell lymphomas. The light- and heavy-chain variable regions of 2B8 were cloned, after amplification by the polymerase ...
Mitchell   +9 more
semanticscholar   +1 more source

Targeting PRAME directly or via EZH2 inhibition overcomes retinoid resistance and represents a novel therapy for keratinocyte carcinoma

open access: yesMolecular Oncology, EarlyView.
The study evaluated the function and therapeutic implications of PRAME in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The findings demonstrate that PRAME impairs keratinocyte differentiation pathways. Furthermore, PRAME impairs anticancer response to retinoid compounds in BCC and SCC cells.
Brandon Ramchatesingh   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy